The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells

This publication has 125 references indexed in Scilit:

• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
  British Journal of Cancer, 2010
• Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
  JAMA, 2008
• Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
  Gynecologic Oncology, 2008
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
• Hypoxia-inducible factor–2 (HIF-2) regulates hepatic erythropoietin in vivo
  Journal of Clinical Investigation, 2007
• Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial
  European Journal of Cancer, 2005
• Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway
  Oncogene, 2004
• Cisplatin: mode of cytotoxic action and molecular basis of resistance
  Oncogene, 2003
• Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. final results of a randomized phase III study
  European Journal of Cancer, 2001
• Erythropoietin stimulates proliferation of human renal carcinoma cells
  Kidney International, 2000